Bupivacaine/meloxicam
< Bupivacaine
| Combination of | |
|---|---|
| Bupivacaine | Local anesthetic |
| Meloxicam | Nonsteroidal anti-inflammatory drug (NSAID) |
| Clinical data | |
| Trade names | Zynrelef |
| Other names | HTX-011 |
| License data |
|
| Routes of administration | Intralesional, infiltration |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Bupivacaine/meloxicam, sold under the brand name Zynrelef, is a fixed-dose combination medication used to treat pain in small to medium-sized wounds after surgery. It contains bupivacaine and meloxicam.
The most common side effects of bupivacaine/meloxicam are dizziness, constipation, vomiting, and headache.
It was authorized for medical use in the European Union in September 2020, and approved in the United States in May 2021.